603538.SH
美诺华
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 26.40
−7.40%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.6B | 1.5B | 1.4B | 1.2B | 1.5B |
| Cost of Revenue | 1.0B | 976.4M | 925.1M | 840.9M | 872.8M |
| Gross Profit | 531.4M | 526.7M | 447.7M | 375.6M | 584.2M |
| Operating Expenses | |||||
| R&D Expense | 103.9M | 109.4M | 99.7M | 95.3M | 98.2M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 148.2M | 144.8M | 158.3M | 164.0M | 202.7M |
| Selling & Marketing Expense | 72.2M | 76.6M | 62.0M | 51.4M | 50.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 388.3M | 385.7M | 369.0M | 350.5M | 373.0M |
| Cost and Expenses | 1.4B | 1.4B | 1.3B | 1.2B | 1.2B |
| Operating Income (EBIT) | 139.3M | 133.6M | 92.6M | 18.7M | 405.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 138.0M | 129.8M | 87.0M | 8.0M | 384.2M |
| Income Tax Expense | 22.6M | 23.7M | 10.9M | (8.2M) | 16.4M |
| Bottom Line | |||||
| Net Income | 112.2M | 102.2M | 66.8M | 11.6M | 338.9M |
| Earnings from Cont. Ops | 115.4M | 106.1M | 76.0M | 16.2M | 367.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 112.2M | 102.2M | 66.8M | 11.6M | 338.9M |
| Per Share | |||||
| Basic EPS | CN¥0.50 | CN¥0.48 | CN¥0.31 | CN¥0.05 | CN¥1.61 |
| Diluted EPS | CN¥0.50 | CN¥0.47 | CN¥0.31 | CN¥0.05 | CN¥1.49 |
| Revenue Per Share | CN¥7.03 | CN¥7.06 | CN¥6.37 | CN¥5.25 | CN¥6.92 |
| Shares | |||||
| Basic Shares Outstanding | 222.6M | 213.0M | 215.5M | 231.7M | 210.5M |
| Diluted Shares Outstanding | 222.6M | 213.0M | 215.5M | 231.7M | 210.5M |
| Profitability Metrics | |||||
| EBITDA | — | 270.3M | 226.7M | 140.0M | 511.1M |
| D&A | — | 136.8M | 134.1M | 121.3M | 105.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026